Skip to main content

Table 8 Trials of mTOR inhibitors in early-stage breast cancer: preoperative therapy

From: Antiangiogenic therapy for breast cancer

Reference Phase Number of patients Treatment Response
Macaskill et al. [85] II 30 Everolimus (14 days prior to surgery) Reduced cell proliferation
Baselga et al. [86] II (randomised) 270 Everolimus + letrozole RR 68%
    Letrozole 59%
  1. mTOR, mammalian target of rapamycin; RR, response rate